[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538744":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":30,"responsibleParty":42,"collaborators":30,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":30,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":73,"whyStopped":30,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":30},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"4-aminopyridine","ACTIVE_COMPARATOR","Study drug: dalfampridine (generic) 10mg ER capsule",[13],"Drug: 4-Aminopyridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo-1 capsule",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","4-Aminopyridine","Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome",[9],[27],"4AP",{"type":6,"name":15,"description":24,"armGroupLabels":29,"otherNames":30},[15],null,[32],{"name":33,"affiliation":5,"role":34},"John Elfar, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Carly Deal","CONTACT","520-626-4656","carlyjdeal@arizona.edu",{"name":33,"role":38,"phone":30,"phoneExt":30,"email":30},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","John Elfar","Tenured Professor, Chairman, Department of Orthopaedic Surgery","100538744","phase-2-4ap-for-carpal-tunnel-syndrome-cts-100538744",false,"NCT06294821","4AP for Carpal Tunnel Syndrome (CTS)","4-Aminopyridine to Delay Carpal Tunnel Release or Resolve Carpal Tunnel Syndrome","CTS","Inclusion Criteria:\n\n* Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)\n* Standard of care EDX testing within 6 months of study enrollment\n* Cognitive ability to report sensory and motor deficit during examination.\n* Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.\n* Adults subject aged 18-90\n* Ability to give written informed consent.\n* Capable of safely undergoing electrodiagnostic testing (EDX).\n* Availability for all study visits.\n\nExclusion Criteria:\n\n* Inability to complete twice daily dosing during 6 week treatment period.\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.","ALL","18 Years","90 Years",{"count":58,"type":59},160,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.",[65,66],"Compression Neuropathy","Carpal Tunnel Syndrome",[68,69,70,27,52,71,72],"4 aminopyridine","carpal tunnel syndrome","CTR","Carpal tunnel release","compression neuropathy","NOT_YET_RECRUITING","2026-01-22",{"date":76,"type":77},"2026-01-26","ACTUAL",{"date":79,"type":59},"2026-11",{"date":81,"type":59},"2028-07",{"name":44,"class":6}]